Assessment of Safety, Tolerability and Pharmacokinetics of Single Ascending Subcutaneous Doses of MOR107 in Healthy Male Subjects and Pharmacodynamics in Healthy Male Subjects on a Low Sodium Diet
This is the first in human study of MOR107. It is a 2 part, single centre, double-blind, randomised, placebo-controlled study in healthy male subjects. Part 1 is a single ascending dose study, and Part 2 is a parallel group, dose range finding study in healthy male subjects on a low sodium diet.
100 项与 LanthioPep BV 相关的临床结果
0 项与 LanthioPep BV 相关的专利(医药)
100 项与 LanthioPep BV 相关的药物交易
100 项与 LanthioPep BV 相关的转化医学